BEIJING, China and CAMBRIDGE, Mass., Oct. 10, 2018 (GLOBE NEWSWIRE) — BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biopharmaceutical aggregation focused on developing and commercializing avant-garde molecularly-targeted and immuno-oncology drugs for the analysis of cancer, today appear that China’s State Medical Insurance Administration (SMIA) has included VIDAZA® (azacitidine for injection) on its civic agreement biologic account (NRDL). VIDAZA is a nucleoside metaic inhibitor and was accustomed in China for patients with intermediate-2 / high-risk myelodysplastic affection (MDS), astute myeloid leukemia (AML) with 20-30% cartilage bottom blasts and abiding myelomonocyte leukemia (CMML). It is marketed in China by BeiGene beneath an absolute authorization from Celgene Corporation.
“VIDAZA became commercially accessible in China in February and is the abandoned accustomed hypomethylating abettor apparent to prolong adaptation for patients with MDS. With this civic agreement coverage, we apprehend added patients to accept an befalling to account from VIDAZA in China,” commented Dr. Xiaobin Wu, General Manager of China and President of BeiGene, Ltd. “BeiGene is committed to convalescent accommodating admission to high-quality, avant-garde blight treatments.”
VIDAZA is recommended by Civic Comprehensive Blight Network (NCCN) Guidelines in the US as a front-line treatment. In a all-around Phase 3 balloon (AZA-001) involving intermediate-2 and high-risk MDS patients, VIDAZA decidedly abiding the average all-embracing adaptation to 24.5 months compared with 15 months for the accepted affliction regimens (CCR- best admiring care, low-dose cytarabine or accelerated chemotherapy) group. In the VIDAZA group, 45% of patients who were abased on red claret corpuscle transfusions at baseline became admixture absolute compared with 11% in the CCR group.There was a college cold acknowledgment amount amid patients brash with VIDAZA (49%) as compared to the CCR arm (29%). VIDAZA additionally delayed the admission of AML for these patients (17.8 months vs.11.5 months). The best accepted brand 3-4 contest were borderline claret cytopenias for all treatments.
“We are admiring that patients in China will accept bigger admission to VIDAZA and added blight treatments listed on the 2018 NRDL,” said Professor Wang Jianxiang, Institute of Hematology and Claret Diseases Hospital, Chinese Academy of Medical Sciences. “VIDAZA is an important analysis for MDS with approved adaptation benefit. The adorning admission to new treatments like VIDAZA could decidedly advance the affliction of our patients.”
About Myelodysplastic Syndrome, Astute Myeloid Leukemia and Abiding Myelomonocyte Leukemia
MDS is a accumulation of altitude that can action back the bloodforming beef in the cartilage bottom become abnormal. This leads to low numbers of one or added types of claret cells. In about one-third of patients with MDS, the ache can advance to a rapidly growing blight of cartilage bottom beef alleged AML.i CMML is a blazon of blight that starts in blood-forming beef of the cartilage bottom and invades the blood; it affects mainly earlier adults. CMML has appearance of both MDS and myeloproliferative ataxia and is brash the best accepted ache amid myelodysplastic/myeloproliferative diseases.ii
About VIDAZA® (Azacitidine for Injection)
VIDAZA is a nucleoside metaic inhibitor adumbrated in China for the analysis of patients with intermediate-2 / high-risk MDS, AML with 20-30% cartilage bottom blasts and CMML. It is marketed in China by BeiGene beneath an absolute authorization from Celgene Corporation.
In the US, VIDAZA is adumbrated for the analysis of patients with the afterward FAB MDS subtypes: adverse anemia (RA) or adverse anemia with belted sideroblasts (RARS) (if accompanied by neutropenia or thrombocytopenia or acute transfusions), adverse anemia with balance blasts (RAEB), adverse anemia with balance blasts in transformation (RAEB-T), and CMML.
Important Assurance Information
VIDAZA is contraindicated in patients with a accepted hypersensitivity to azacitidine or mannitol and in patients with avant-garde cancerous hepatic tumors.
In Abstraction 1 (a randomized, open-label, controlled balloon agitated out in 53 U.S. sites compared the assurance and adeptness of subcutaneous VIDAZA added admiring affliction with admiring affliction abandoned (“observation”) in patients with any of the bristles FAB subtypes of myelodysplastic syndromes (MDS)) and Abstraction 2 (a multi-center, open-label, single-arm abstraction of 72 patients with RAEB, RAEB-T, CMMoL, or AML), best frequently empiric adverse reactions occurring in at atomic 5% of patients by SC avenue were abhorrence (70.5%), anemia (69.5%), thrombocytopenia (65.5%), airsickness (54.1%), agitation (51.8%), leukopenia (48.2%), diarrhea (36.4%), bang armpit erythema (35.0%), ache (33.6%), neutropenia (32.3%), and ecchymosis (30.5%). Added adverse reactions included blackout (18.6%), affliction (16.4%), delirious neutropenia (16.4%), myalgia (15.9%), bang armpit acknowledgment (13.6%), and angst (10.9%). In Abstraction 3, the best accepted adverse reactions by IV avenue additionally included petechiae (45.8%), weakness (35.4%), rigors (35.4%), and hypokalemia (31.3%).
In Abstraction 4 (the AZA-001 adaptation trial, an international, multicenter, open-label, randomized balloon in MDS patients with RAEB, RAEB-T or adapted CMMoL according to FAB allocation and Intermediate-2 and High accident according to IPSS classification), best frequently empiric adverse reactions occurring in at atomic 5% of patients were thrombocytopenia (69.7%), neutropenia (65.7%), anemia (51.4%), ache (50.3%), abhorrence (48.0%), bang armpit erythema (42.9%), and agitation (30.3%). The best frequently empiric adverse reactions in the allotment with NCI CTC Brand 3/4 reactions were neutropenia (61.1%), thrombocytopenia (58.3%), leukopenia (14.9%), anemia (13.7%), and delirious neutropenia (12.6%).
Because analysis with VIDAZA is associated with anemia, neutropenia and thrombocytopenia, complete claret counts should be performed as bare to adviser acknowledgment and/or toxicity, but at a minimum, above-mentioned to anniversary dosing cycle.
Because azacitidine is potentially hepatotoxic in patients with astringent preexisting hepatic impairment, attention is bare in patients with alarmist disease. In addition, azacitidine and its metaites are essentially excreted by the kidneys and the accident of baneful reactions to this biologic may be greater in patients with broken renal function. Because aged patients are added acceptable to accept decreased renal function, it may be advantageous to adviser renal function.
VIDAZA may account fetal abuse back administered to a abundant woman. Females of changeable abeyant should be brash to abstain abundance during analysis with VIDAZA. Males with changeable animal ally of changeable abeyant should not ancestor a adolescent and should use able contraception during analysis with VIDAZA.
The accent of the biologic to the mother should be taken into application afore the feeding mothers adjudge to abandon feeding or the drug.
BeiGene is a global, commercial-stage, research-based biotechnology aggregation focused on molecularly-targeted and immuno-oncology blight therapeutics. With a aggregation of over 1,300 advisers in China, the United States, Australia and Switzerland, BeiGene is advancing a activity consisting of atypical articulate baby molecules and monoclonal antibodies for cancer. BeiGene is additionally alive to actualize aggregate solutions aimed to accept both a allusive and abiding appulse on blight patients. BeiGene markets ABRAXANE® (nanoparticle albumin–bound paclitaxel), REVLIMID® (lenalidomide), and VIDAZA® (azacitidine) in China beneath a authorization from Celgene Corporation.iii
This columnist absolution contains advanced statements aural the acceptation of the Private Balance Litigation Reform Act of 1995 and added federal balance laws, including statements apropos BeiGene’s commercialization of VIDAZA® in China, the abeyant allowances of VIDAZA®, and BeiGene’s affairs to commercialize added drugs in China. Actual after-effects may alter materially from those adumbrated in the advanced statements as a aftereffect of assorted important factors, including BeiGene’s adeptness to authenticate the adeptness and assurance of its biologic candidates; the analytic after-effects for its biologic candidates, which may not abutment added development or business approval; accomplishments of authoritative agencies, which may affect the initiation, timing and advance of analytic trials and business approval; BeiGene’s adeptness to accomplish bartering success for its marketed biologic articles and biologic candidates, if approved; BeiGene’s adeptness to access and advance aegis of bookish acreage for its technology and drugs; BeiGene’s assurance on third parties to conduct biologic development, accomplishment and added services; BeiGene’s bound operating history and BeiGene’s adeptness to access added allotment for operations and to complete the development and commercialization of its biologic candidates, as able-bodied as those risks added absolutely discussed in the area advantaged “Risk Factors” in BeiGene’s best contempo annual address on Form 10-Q, as able-bodied as discussions of abeyant risks, uncertainties, and added important factors in BeiGene’s consecutive filings with the U.S. Balance and Exchange Commission. All advice in this columnist absolution is as of the date of this columnist release, and BeiGene undertakes no assignment to amend such advice unless appropriate by law.
Investor ContactCraig West 1 [email protected]
Media ContactLiza Heapes 1 [email protected]
iii ABRAXANE®, REVLIMID®, and VIDAZA® are registered trademarks of Celgene Corporation
11 Taboos About Label Manager 11 You Should Never Share On Twitter | Label Manager 11 – label manager 160
| Encouraged to our website, in this particular time We’ll teach you in relation to label manager 160